EGFR and lung cancer: ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; DFS, disease‐free survivals; EGFR‐TKI, tyrosine kinase inhibitors of epidermal growth factor receptor activating mutation; mPFS, median progression‐free survival; NSCLC, nonsmall cell lung cancer; ORR, objective response rate; OS, overall survival; PEXG, cisplatin, epirubicin, capecitabine, gemcitabine; PFS, progression‐free survival; SOC, standard of care.